Murine Models of Inflammatory Bowel Disease (IBD): Challenges of Modeling Human Disease

被引:56
作者
Devoss, Jason [1 ]
Diehl, Lauri [2 ]
机构
[1] Genentech Inc, Dept Immunol, San Francisco, CA 94080 USA
[2] Genentech Inc, Dept Pathol, San Francisco, CA 94080 USA
关键词
preclinical research and development; animal models; mouse; gastrointestinal system; inflammation; SODIUM-INDUCED COLITIS; CROHNS-DISEASE; ULCERATIVE-COLITIS; INTESTINAL INFLAMMATION; ESCHERICHIA-COLI; OLMSTED COUNTY; NITRIC-OXIDE; SCID MICE; PREVALENCE; CELLS;
D O I
10.1177/0192623313509729
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Animal models of human disease are a critical tool in both basic research and drug development. The results of preclinical efficacy studies often inform progression of therapeutic candidates through the drug development pipeline; however, the extent to which results in inflammatory bowel disease (IBD) models predict human drug response is an ongoing concern. This review discusses how murine models are currently being used in IBD research. We focus on the considerations and caveats for commonly used models in preclinical efficacy studies and discuss the value of models that utilize specific pathogenic pathways of interest rather than model all aspects of human disease.
引用
收藏
页码:99 / 110
页数:12
相关论文
共 106 条
[1]   MECHANISMS OF DISEASE Inflammatory Bowel Disease [J].
Abraham, Clara ;
Cho, Judy H. .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (21) :2066-2078
[2]   N-acetylcysteine improves redox status, mitochondrial dysfunction, mucin-depleted crypts and epithelial hyperplasia in dextran sulfate sodium-induced oxidative colitis in mice [J].
Amrouche-Mekkioui, Ilhem ;
Djerdjouri, Bahia .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2012, 691 (1-3) :209-217
[3]  
Anderson P, 2000, ANN RHEUM DIS, V59, P3
[4]  
Aranda R, 1997, J IMMUNOL, V158, P3464
[5]   Mesenchymal cell targeting by TNF as a common pathogenic principle in chronic inflammatory joint and intestinal diseases [J].
Armaka, Maria ;
Apostolaki, Maria ;
Jacques, Peggy ;
Kontoyiannis, Dimitris L. ;
Elewaut, Dirk ;
Kollias, George .
JOURNAL OF EXPERIMENTAL MEDICINE, 2008, 205 (02) :331-337
[6]   Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype [J].
Arnott, IDR ;
Landers, CJ ;
Nimmo, EJ ;
Drummond, HE ;
Smith, BKR ;
Targan, SR ;
Satsangi, J .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (12) :2376-2384
[7]   Phase II failures: 2008-2010 [J].
Arrowsmith, John .
NATURE REVIEWS DRUG DISCOVERY, 2011, 10 (05) :1-1
[8]   TRIAL WATCH Phase III and submission failures: 2007-2010 [J].
Arrowsmith, John .
NATURE REVIEWS DRUG DISCOVERY, 2011, 10 (02) :1-1
[9]   Long-term outcome of tumor necrosis factor alpha antagonist's treatment in pediatric Crohn's disease [J].
Assa, Amit ;
Hartman, Corina ;
Weiss, Batia ;
Broide, Efrat ;
Rosenbach, Yoram ;
Zevit, Noam ;
Bujanover, Yoram ;
Shamir, Raanan .
JOURNAL OF CROHNS & COLITIS, 2013, 7 (05) :369-376
[10]   Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework [J].
Atkinson, AJ ;
Colburn, WA ;
DeGruttola, VG ;
DeMets, DL ;
Downing, GJ ;
Hoth, DF ;
Oates, JA ;
Peck, CC ;
Schooley, RT ;
Spilker, BA ;
Woodcock, J ;
Zeger, SL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) :89-95